AstraZeneca PLC (AZNN) - Net Assets

Latest as of September 2025: MX$45.97 Billion MXN ≈ $2.65 Billion USD

Based on the latest financial reports, AstraZeneca PLC (AZNN) has net assets worth MX$45.97 Billion MXN (≈ $2.65 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (MX$114.46 Billion ≈ $6.59 Billion USD) and total liabilities (MX$68.48 Billion ≈ $3.94 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore how efficiently does AstraZeneca PLC generate cash to assess how effectively this company generates cash.

Key Net Assets Metrics

Metric	Value
Current Net Assets	MX$45.97 Billion
% of Total Assets	40.16%
Annual Growth Rate	7.6%
5-Year Change	161.36%
10-Year Change	120.82%
Growth Volatility	46.44

AstraZeneca PLC - Net Assets Trend (2014–2024)

This chart illustrates how AstraZeneca PLC's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see AZNN company net worth.

Annual Net Assets for AstraZeneca PLC (2014–2024)

The table below shows the annual net assets of AstraZeneca PLC from 2014 to 2024. Read AstraZeneca PLC debt and liabilities for a breakdown of total debt and financial obligations.

Year	Net Assets	Change
2024-12-31	MX$40.87 Billion ≈ $2.35 Billion	+4.35%
2023-12-31	MX$39.17 Billion ≈ $2.25 Billion	+5.69%
2022-12-31	MX$37.06 Billion ≈ $2.13 Billion	-5.67%
2021-12-31	MX$39.29 Billion ≈ $2.26 Billion	+151.23%
2020-12-31	MX$15.64 Billion ≈ $899.97 Million	+7.14%
2019-12-31	MX$14.60 Billion ≈ $840.00 Million	+3.93%
2018-12-31	MX$14.04 Billion ≈ $808.24 Million	-15.61%
2017-12-31	MX$16.64 Billion ≈ $957.75 Million	-0.16%
2016-12-31	MX$16.67 Billion ≈ $959.31 Million	-9.94%
2015-12-31	MX$18.51 Billion ≈ $1.07 Billion	-5.79%
2014-12-31	MX$19.65 Billion ≈ $1.13 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to AstraZeneca PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 74.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	MX$3.16 Billion	7.75%
Other Components	MX$37.63 Billion	92.25%
Total Equity	MX$40.79 Billion	100.00%

AstraZeneca PLC Competitors by Market Cap

The table below lists competitors of AstraZeneca PLC ranked by their market capitalization.

Company	Market Cap
Morgan Stanley SA:MSBR34	$293.89 Billion
AstraZeneca PLC NASDAQ:AZN	$294.17 Billion
GE Aerospace NYSE:GE	$298.49 Billion
Industrial and Commercial Bank of China Ltd SHG:601398	$299.05 Billion
General Electric Company SA:GEOO34	$289.12 Billion
Novartis AG MX:NVSN	$288.37 Billion
Lam Research Corp NASDAQ:LRCX	$287.98 Billion
Contemporary Amperex Technology Co Ltd Class A SHE:300750	$286.97 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in AstraZeneca PLC's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 39,143,000,000 to 40,786,000,000, a change of 1,643,000,000 (4.2%).
Net income of 7,035,000,000 contributed positively to equity growth.
Dividend payments of 4,629,000,000 reduced retained earnings.
Other factors decreased equity by 720,000,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	MX$7.04 Billion	+17.25%
Dividends Paid	MX$4.63 Billion	-11.35%
Other Changes	MX$-720.00 Million	-1.77%
Total Change	MX$-	4.20%

Book Value vs Market Value Analysis

This analysis compares AstraZeneca PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 61.89x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 137.79x to 61.89x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	MX$11.81	MX$1628.00	x
2018-12-31	MX$9.84	MX$1628.00	x
2019-12-31	MX$10.00	MX$1628.00	x
2020-12-31	MX$11.90	MX$1628.00	x
2021-12-31	MX$25.34	MX$1628.00	x
2022-12-31	MX$23.90	MX$1628.00	x
2023-12-31	MX$25.25	MX$1628.00	x
2024-12-31	MX$26.30	MX$1628.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently AstraZeneca PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 17.25%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.01%
• Asset Turnover: 0.52x
• Equity Multiplier: 2.55x
Recent ROE (17.25%) is above the historical average (14.06%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	6.28%	4.64%	0.45x	2.99x	MX$-729.70 Million
2015	15.28%	11.43%	0.41x	3.25x	MX$976.00 Million
2016	23.56%	15.21%	0.37x	4.21x	MX$2.01 Billion
2017	20.06%	13.36%	0.35x	4.23x	MX$1.50 Billion
2018	17.28%	9.76%	0.36x	4.86x	MX$908.20 Million
2019	10.17%	5.47%	0.40x	4.68x	MX$22.30 Million
2020	20.46%	12.01%	0.40x	4.27x	MX$1.63 Billion
2021	0.29%	0.30%	0.36x	2.68x	MX$-3.81 Billion
2022	8.88%	7.41%	0.46x	2.61x	MX$-415.70 Million
2023	15.21%	13.00%	0.45x	2.58x	MX$2.04 Billion
2024	17.25%	13.01%	0.52x	2.55x	MX$2.96 Billion

Industry Comparison

This section compares AstraZeneca PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $48,775,333,333
Average return on equity (ROE) among peers: 58.65%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
AstraZeneca PLC (AZNN)	MX$45.97 Billion	6.28%	1.49x	$290.50 Billion
GlaxoSmithKline plc (GSKN)	$10.10 Billion	148.14%	4.96x	$109.41 Billion
Novartis AG (NVSN)	$77.12 Billion	23.06%	0.71x	$288.37 Billion
Sanofi (SNYN)	$59.11 Billion	4.75%	0.91x	$117.45 Billion

About AstraZeneca PLC

MX:AZNN Mexico Drug Manufacturers - General

Market Cap

$290.50 Billion

MX$5.05 Trillion MXN

Market Cap Rank

#53 Global

#1 in Mexico

Share Price

MX$1628.00

Change (1 day)

+1.25%

52-Week Range

MX$1285.00 - MX$1722.60

All Time High

MX$1751.39